METHANOLIC LEAF EXTRACT OF Abutilon indicum ATTENUATES ADIPOSITY AND DYSLIPIDAEMIA IN HIGH-FAT DIET-INDUCED OBESE SWISS ALBINO MICE: BIOCHEMICAL AND HISTOPATHOLOGICAL EVIDENCE

Authors

  • Sharandeep Kaur Department of Phamacy, Aakash Institute of Medical Sciences, Nalagarh, Distt. Solan, Himachal Pradesh-India https://orcid.org/0009-0003-6707-432X
  • Sarbjot Singh Department of Pharmacy, Himachal Pharmacy College,Nalagarh (HP)-India https://orcid.org/0009-0005-8547-2043
  • Aaditya Thakur Department of Pharmacy, Himachal Pharmacy College,Nalagarh (HP)-India
  • Anita Devi Department of Pharmacy, Himachal Pharmacy College,Nalagarh (HP)-India
  • Vasundhra Department of Pharmacy, Himachal Pharmacy College,Nalagarh (HP)-India
  • Anchel Sharma Department of Pharmacy, Himachal Pharmacy College,Nalagarh (HP)-India
  • Anish Verma Department of Pharmacy, Amar Shaheed Baba Ajeet Singh Jhujhar Singh Memorial College,Bela(Ropar)-India
  • Sonika Rattan Department of Pharmacy, Institute of Pharmaceutical Sciences, IET Bhaddal,Ropar-India

DOI:

https://doi.org/10.67145/wernt456

Keywords:

Abutilon indicum, obesity, high-fat diet, methanolic extract, lipid profile, orlistat

Abstract

Background: Obesity is a multifactorial metabolic disorder that rarely travels alone; it is usually accompanied by abnormal blood lipids and disturbed glucose regulation. This study asked whether a methanolic leaf extract of Abutilon indicum (MEAI) could limit weight gain and metabolic disturbance in mice made obese with a high-fat diet (HFD), with orlistat serving as the reference drug.
Methods: Leaves of A. indicum were extracted with methanol in a Soxhlet apparatus. The extract was screened phytochemically and its total flavonoid and total phenolic contents were measured. Swiss albino mice were divided into five groups (n = 6 per group): normal control, HFD control, orlistat (10 mg/kg), MEAI (200 mg/kg) and MEAI (400 mg/kg). Treatments were given orally from day 22 to day 49 of a 49-day HFD protocol. We followed body weight, feed intake, body mass index (BMI), Lee index, serum biochemistry, organ weights and histopathology.
Results: The extract yield was 22% w/w. Preliminary screening showed alkaloids, flavonoids, tannins, phenols, terpenoids, saponins, steroids and glycosides. Total flavonoid and phenolic contents were 34.92 ± 1.161 mg QE/g and 207.40 ± 2.347 mg GAE/g of crude extract, respectively. At week 7, MEAI-treated mice weighed 28% (200 mg/kg) and 37% (400 mg/kg) less than HFD controls, and the lipid profile moved in the same favourable direction. In general, the 400 mg/kg dose outperformed the 200 mg/kg dose. Liver and mesenteric fat-pad histology also showed less marked HFD-related change in treated animals.
Conclusion: MEAI appears to have anti-obesity and lipid-modulating activity in this mouse model. Before any claim about therapeutic value can be made, the findings need confirmation with fully documented statistics, a chemically standardized extract and a proper safety assessment.

 

 

References

1.Haslam DW, James WPT. Obesity. Lancet. 2005;366(9492):1197–1209.

2.Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846.

3.Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–781.

4.O'Rahilly S, Farooqi IS. Genetics of obesity. Philos Trans R Soc Lond B Biol Sci. 2006;361(1471):1095–1105.

5.Campfield LA, Smith FJ, Burn P. Strategies and potential molecular targets for obesity treatment. Science. 1998;280(5368):1383–1387.

6.Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–923.

7.Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114(2):147–152.

8.Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254–266.

9.Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(Suppl 3):S12–S23.

10.Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194–1199.

11.Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369(9555):71–77.

12.Moro CO, Basile G. Obesity and medicinal plants. Fitoterapia. 2000;71(Suppl 1):S73–S82.

13.Yun JW. Possible anti-obesity therapeutics from nature – a review. Phytochemistry. 2010;71(14–15):1625–1641.

14.Birari RB, Bhutani KK. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug Discov Today. 2007;12(19–20):879–889.

15.Wang S, Moustaid-Moussa N, Chen L, et al. Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014;25(1):1–18.

16.Hasani-Ranjbar S, Nayebi N, Larijani B, Abdollahi M. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol. 2009;15(25):3073–3085.

17.Kirtikar KR, Basu BD. Indian Medicinal Plants. 2nd ed. Vol. 1. Dehradun: Bishen Singh Mahendra Pal Singh; 1980:314–315.

18.Seetharam YN, Chalageri G, Setty SR. Hypoglycemic activity of Abutilon indicum leaf extracts in rats. Fitoterapia. 2002;73(2):156–159.

19.Porchezhian E, Ansari SH. Hepatoprotective activity of Abutilon indicum on experimental liver damage in rats. Phytomedicine. 2005;12(1–2):62–64.

20.Harborne JB. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. 3rd ed. London: Chapman & Hall; 1998.

21.Trease GE, Evans WC. Pharmacognosy. 13th ed. London: Baillière Tindall; 1989.

22.Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. Pune: Nirali Prakashan; 2006.

23.Chang CC, Yang MH, Wen HM, Chern JC. Estimation of total flavonoid content in propolis by two complementary colorimetric methods. J Food Drug Anal. 2002;10(3):178–182.

24.Singleton VL, Rossi JA. Colorimetry of total phenolics with phosphomolybdic–phosphotungstic acid reagents. Am J Enol Vitic. 1965;16(3):144–158.

25.Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.

26.Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. Diabetes. 1988;37(9):1163–1167.

27.Buettner R, Schölmerich J, Bollheimer LC. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring). 2007;15(4):798–808.

28.Novelli ELB, Diniz YS, Galhardi CM, et al. Anthropometrical parameters and markers of obesity in rats. Lab Anim. 2007;41(1):111–119.

29.Bernardis LL, Patterson BD. Correlation between 'Lee index' and carcass fat content in weanling and adult female rats with hypothalamic lesions. J Endocrinol. 1968;40(4):527–528.

30.Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50(272):1096–1121.

Downloads

Published

2025-11-29

How to Cite

Sharandeep Kaur, Sarbjot Singh, Aaditya Thakur, Anita Devi, Vasundhra, Anchel Sharma, Anish Verma, & Sonika Rattan. (2025). METHANOLIC LEAF EXTRACT OF Abutilon indicum ATTENUATES ADIPOSITY AND DYSLIPIDAEMIA IN HIGH-FAT DIET-INDUCED OBESE SWISS ALBINO MICE: BIOCHEMICAL AND HISTOPATHOLOGICAL EVIDENCE. Journal of Population Therapeutics and Clinical Pharmacology, 32(10), 2513-2525. https://doi.org/10.67145/wernt456
More Citation Formats

Issue

Section

Articles

How to Cite

Sharandeep Kaur, Sarbjot Singh, Aaditya Thakur, Anita Devi, Vasundhra, Anchel Sharma, Anish Verma, & Sonika Rattan. (2025). METHANOLIC LEAF EXTRACT OF Abutilon indicum ATTENUATES ADIPOSITY AND DYSLIPIDAEMIA IN HIGH-FAT DIET-INDUCED OBESE SWISS ALBINO MICE: BIOCHEMICAL AND HISTOPATHOLOGICAL EVIDENCE. Journal of Population Therapeutics and Clinical Pharmacology, 32(10), 2513-2525. https://doi.org/10.67145/wernt456